|
1
|
Montagner C, Bricou A, Selle F, Kafé H, Mauhin W, Fredeau L, Duval-Chopard L, Slama J, Durand P, Beal C, London J, Lidove O. [Glassy cell carcinoma of the uterine cervix: An aggressive type of cancer]. Rev Med Interne 2019; 40:754-757. [PMID: 31431320 DOI: 10.1016/j.revmed.2019.07.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2019] [Revised: 06/19/2019] [Accepted: 07/17/2019] [Indexed: 11/19/2022]
Abstract
INTRODUCTION Cervical cancer is the twelfth most frequent cancer in women in France. Glassy cell carcinoma is a rare histological entity, rapidly aggressive, associated with a poor prognosis. CASE REPORT A 30-year-old woman was admitted in an internal medicine department for polyarthralgia with high grade fever, evolving for 3 weeks. There was an inflammatory syndrome. The 18-FDG-PET-scan showed inflammatory lymph nodes as well as disseminated osteolytic lesions, and a primitive pelvic tumor. A 3cm tumor of the cervix was found during the gynaecologic examination. Histological analysis elicited a high-index mitotic carcinoma, glassy cell carcinoma type. Despite chemotherapy, the outcome was poor, with early death occurring after three months of follow-up. CONCLUSION The glassy cell carcinoma of the cervix should be considered as an aetiology of bone metastases in young female patients.
Collapse
Affiliation(s)
- C Montagner
- Service de médecine interne, Groupe Hospitalier Diaconesses Croix Saint Simon, rue d'Avron, 75020 Paris, France.
| | - A Bricou
- Service de chirurgie gynécologique et mammaire, Groupe Hospitalier Diaconesses Croix Saint Simon, rue d'Avron, 75020 Paris, France
| | - F Selle
- Service d'oncologie, Groupe Hospitalier Diaconesses Croix Saint Simon, rue d'Avron 75020 Paris, France
| | - H Kafé
- Centre de pathologie, 19, rue de Passy, 75016, France
| | - W Mauhin
- Service de médecine interne, Groupe Hospitalier Diaconesses Croix Saint Simon, rue d'Avron, 75020 Paris, France
| | - L Fredeau
- Service de médecine interne, Groupe Hospitalier Diaconesses Croix Saint Simon, rue d'Avron, 75020 Paris, France
| | - L Duval-Chopard
- Service de médecine interne, Groupe Hospitalier Diaconesses Croix Saint Simon, rue d'Avron, 75020 Paris, France
| | - J Slama
- Paris Service de médecine nucléaire, Hôpital Beaujon, 100, boulevard du Général Leclerc, 92110 Clichy, France
| | - P Durand
- Service de radiologie, Groupe Hospitalier Diaconesses Croix Saint Simon, rue d'Avron, 75020 Paris, France
| | - C Beal
- Service de rhumatologie, Groupe Hospitalier Diaconesses Croix Saint Simon, rue d'Avron, 75020 Paris, France
| | - J London
- Service de médecine interne, Groupe Hospitalier Diaconesses Croix Saint Simon, rue d'Avron, 75020 Paris, France
| | - O Lidove
- Service de médecine interne, Groupe Hospitalier Diaconesses Croix Saint Simon, rue d'Avron, 75020 Paris, France
| |
Collapse
|
|
2
|
Sousa GFD, Wlodarczyk SR, Monteiro G. Carboplatin: molecular mechanisms of action associated with chemoresistance. BRAZ J PHARM SCI 2014. [DOI: 10.1590/s1984-82502014000400004] [Citation(s) in RCA: 49] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
Carboplatin is a derivative of cisplatin; it has a similar mechanism of action, but differs in terms of structure and toxicity. It was approved by the FDA in the 1980s and since then it has been widely used in the treatment of several tumor types. This agent is characterized by its ability to generate lesions in DNA through the formation of adducts with platinum, thereby inhibiting replication and transcription and leading to cell death. However, its use can lead to serious inconvenience arising from the development of resistance that some patients acquire during treatment, limiting the scope of its full potential. Currently, the biochemical mechanisms related to resistance are not precisely known. Therefore, knowledge of pathways associated with resistance caused by carboplatin exposure may provide valuable clues for more efficient rational drug design in platinum-based therapy and the development of new therapeutic strategies. In this narrative review, we discuss some of the known mechanisms of resistance to platinum-based drugs, especially carboplatin.
Collapse
|